Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 7/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490933 | 0.92 | F10 (0.57) | F10TP53LMNAENPP2 | |
| SCHEMBL4499868 | 0.90 | F10 (0.49) | F10TP53LMNAPOLBHTT | |
| SCHEMBL4501332 | 0.90 | F10 (0.53) | F10TP53LMNAENPP2 | |
| SCHEMBL4492374 | 0.89 | F10 (0.52) | F10TP53LMNAENPP2POLB | |
| SCHEMBL4508917 | 0.89 | F10 (0.53) | F10TP53LMNAENPP2POLB | |
| SCHEMBL4492429 | 0.85 | LMNA (0.50) | F10TP53LMNAENPP2 | |
| SCHEMBL4495243 | 0.85 | TP53 (0.45) | F10TP53LMNAENPP2POLB | |
| SCHEMBL4492454 | 0.84 | LMNA (0.44) | F10TP53LMNAENPP2 | |
| SCHEMBL4506434 | 0.84 | F10 (0.57) | F10 | |
| SCHEMBL4515541 | 0.84 | F10 (0.57) | F10TP53LMNAPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615549-B2 | Substituted pyrrolidinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-10 | — | — | US | claimed |
| US-20060142263-A1 | NEW SUBSTITUTED PYRROLIDINONES, THEIR MANUFACTURE AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| US-7615549-B2 | Substituted pyrrolidinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-10 | — | — | US | disclosed |
| US-20060142263-A1 | NEW SUBSTITUTED PYRROLIDINONES, THEIR MANUFACTURE AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142263-A1 | NEW SUBSTITUTED PYRROLIDINONES, THEIR MANUFACTURE AND THEIR USE AS MEDICAMENTS | PYCR1, OAT, UROD | F10 814/4885TP53 3367/4885LMNA 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.